Pharmaceutical toxicology experts are integral to ensuring the safety and efficacy of new drugs throughout the development process. They assess the potential risks of pharmaceutical compounds by conducting preclinical studies, analyzing data, and interpreting toxicological findings to inform drug development decisions. Their expertise is crucial in identifying potential adverse effects and determining safe dosage levels, thereby protecting public health and ensuring regulatory compliance.
Pharmaceutical toxicology experts collaborate closely with research and development teams, regulatory agencies, and other stakeholders to provide toxicological insights during the drug design process. They play a key role in preparing regulatory submissions, such as pre-IND and IND packages, and may participate in meetings with agencies like the FDA and EMA to address safety concerns and support clinical development. Their work not only contributes to the development of safe and effective medications but also supports the pharmaceutical industry’s efforts to meet evolving regulatory requirements and market demands. Their contributions are pivotal in shaping the future of personalized medicine and targeted therapies. Additionally, pharmaceutical toxicology experts often engage in post-market surveillance to monitor the long-term safety of drugs, identifying rare or delayed adverse effects that may not have been apparent during clinical trials. They also contribute to the development of safety standards and guidelines that influence public health policies and practices.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia